Rutgers Cancer Institute of New Jersey is leading a single-arm, phase II study for adults with advanced hepatocellular carcinoma and mild liver impairment.
Researchers want to learn whether it is safe to give atezolizumab and bevacizumab to participants with advanced liver cancer and Child-Pugh B7 liver dysfunction. They also plan to estimate the overall response rate, disease control rate, duration of response, progression-free survival, and overall survival in these patients using this combined therapy.
March 19, 2021: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium highlights current research, innovations, appointments, publications, and general news across member institutions. Read More
Sept. 1, 2021: The Big Ten Cancer Research Consortium Foundation, Inc. (the “Foundation”) requests proposals for the creation and implementation of a development/fundraising program. The Foundation is a philanthropic organization created to raise funds to support collaborative oncology research activities of the Big Ten Cancer Research Consortium (the “Consortium”). The Consortium includes 15 academic cancer centers united to conduct highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities (see https://bigtencrc.org/). The Foundation anticipates a two-year contractual commitment during which the vendor will create and implement a program to raise funds to support the Consortium’s research. The vendor will contract... Read More
March 18, 2021: Big Ten basketball fans have good reason to celebrate this month: The conference is bringing nine teams to the NCAA Men’s Basketball Tournament – leading all other conferences! We’re excited for tip-off, and so are the Big Ten CRC cancer center directors! While basketball teams battle it out on the court, our directors are lacing up their shoes every day to take on cancer. We could not wish for a better team!
Get to know our team:
HOWARD H. BAILEY, MDDirector, University of Wisconsin Carbone Cancer CenterKey Stats for UW Carbone Cancer Center: One of the original 6 NCI-designated Comprehensive Cancer Centers in 1973. Dr. Charles Heidelberger invented and developed 5-FU here. NCI... Read More
March 9, 2021: Big Ten Cancer Research Consortium investigators highlighted two ongoing studies during the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, held virtually January 28-31. Melissa Yan, MD (pictured left), a hematology-oncology fellow at the Indiana University School of Medicine, presented a featured poster (FP01.04) on BTCRC-LUN19-396, a phase II study of adjuvant chemotherapy plus atezolizumab in stage IB-IIIA resected non-small cell lung cancer (NSCLC) and clearance of circulating tumor DNA (ctDNA). Emily Sisel (pictured right), an MD candidate at the University of Illinois College of Medicine, presented Read More
March 8, 2021: Big Ten Cancer Research Consortium investigators presented a virtual poster highlighting BTCRC-GU16-043, a Big Ten CRC phase Ib/II study of durvalumab and guadecitabine in advanced kidney cancer, during the 2021 Genitourinary Cancers Symposium. The study, led by the University of Michigan Rogel Cancer Center, investigates whether adding guadecitabine, a drug that targets DNA methylation, might increase the proportion of patients with advanced clear cell renal carcinoma (ccRCC) who respond to treatment with durvalumab, a checkpoint inhibitor that... Read More
March 3, 2021: This month, the Big Ten Cancer Research Consortium highlights our member, the University of Illinois Cancer Center at the University of Illinois at Chicago. In this member feature, we shine the spotlight on two University of Illinois at Chicago investigators who are actively involved in consortium studies and working groups: Irum Khan, MD, and Kent Hoskins, MD.
March 3, 2021: Big Ten basketball teams battle it out on the hardwood each March in hopes of making it to the madness that’s the national tournament, but this year the institutions are setting aside their rivalries to team up for Screening Madness. Colorectal Cancer Awareness Month tips off each March, and the Big Ten Cancer Research Consortium and The Blue Hat Foundation, a Chicago-based colorectal cancer organization founded by colorectal cancer survivor Candace Henley, are uniting to raise awareness of the disease with a goal of increasing screenings. Colorectal cancer starts in the colon or the rectum, and nearly always develops from precancerous polyps, or... Read More
February 17, 2021: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium highlights current research, appointments, publications, general news, and expansions across member campuses. Read More
February 15, 2021: Researchers leading a Big Ten Cancer Research Consortium phase Ib/II study of concurrent durvalumab and radiation therapy (DUART) in adults with unresectable, cisplatin ineligible locally advanced bladder cancer, reported promising results during recent virtual scientific meetings. Monika Joshi, MD, MRCP, sponsor-investigator of the BTCRC-GU15-023 study, presented a rapid abstract session during the 2021 Genitourinary Cancers Symposium on Friday, Feb. 12, that built upon data previously reported by study co-author Leonard C. Tuanquin, MD, during an oral scientific session at the ASTRO Annual Meeting, on Sunday, Oct. 25, 2020. Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube